Cell4Pharma tackles your ADME-tox issues based upon their ciPTEC platforms

Cell4Pharma’s mission is to lower drug failure during the clinical phase of drug development due to kidney toxicity.

They envision a world without a risk for renal toxicity for compounds entering clinical stages of drug development. Cell4Pharma aims to reduce the failure rate in late clinical stages due to renal tox below 3% market wide within the next 10 years. Without the use of animal experimentation. This ambition is supported by their human renal cell lines; ciPTEC, validated during extensive collaborations with the pharmaceutical industry. More than 10 years of research lead to the development of robust cell-based assays focusing on the detection of highly specific biomarkers for renal toxicity. ciPTEC consists of three cell lines.

  • ciPTEC expresses the most relevant renal drug transporters endogenously.
  • ciPTEC is an excellent tool to predict pharmaco-kinetics, drug interactions and renal toxicity for potential pharmaceutical compounds.
  • ciPTEC is a highly stable human cell line with maintained tubular characteristics and transporter functionality.

Bio-Connect Life Sciences supplies all their products in the Benelux. If you have any questions, please contact the helpdesk.

Product lines from Cell4Pharma

Newsletter for researchers

We gladly support you by keeping you updated on our latest products and the developments around our services.